Pressmeddelanden
REG
MAR
Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland
Coegin Pharma AB ("Coegin" or "the Company") has entered a distribution agreement with Mercapharm, a fast-growing Polish distributor, through the signing of a limited purchase or...
REG
MAR
Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation
Coegin Pharma AB ("Coegin" or "the Company") has entered a distribution agreement with the Swedish premium retail company Gents AB through the signing of a first limited purchase...
REG
Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025
Summary of the Interim ReportThe second quarter of 2025 has been defined by intense preparation for one of the most important milestones in Coegin Pharma's history - the upcoming...
Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product
The company is pleased to inform that the commercialisation of the first Follicopeptide-based product, expected by the end of this year, is firmly on schedule. Commercial scale p...
REG
Coegin Pharma ändrar språk för informationsgivning till engelska
Coegin Pharma meddelar härmed att bolaget ändrar språk för informationsgivning till endast engelska. Detta innebär att finansiella rapporter och pressmeddelanden endast kommer at...
REG
Coegin Pharma changes language for company communication to English
Coegin Pharma hereby announces that the company will change its language for communication to English only. This means that financial reports and press releases will henceforth b...
Rapporter
Video
Finansiell kalender
Delårsrapport Q3 2025
Delårsrapport
Bokslutskommuniké 2025
Bokslutskommuniké
Om Coegin Pharma
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs ()
Förändring ()
